Nuvation Bio Inc. (NUVB) Cash Flow Statement

The 2024Q2 net loss of $462.5M, driven by a one-time IPR&D charge, contrasts sharply with the $37.3M operating cash outflow, highlighting the non-cash nature of that charge. In 2026Q2, net income of -$62.8M versus operating cash flow of -$5.1M suggests that large non-cash expenses, including SBC and possibly amortization, are inflating the loss. Investors should focus on cash burn rather than net income as the true measure of financial health.

The 2026Q2 FCF of -$5.0M is a significant improvement from the -$52.9M in 2025Q3, but this is largely due to the $31.7M revenue recognition, which appears to be a one-time milestone. Excluding this, the underlying burn rate remains around $40-50M per quarter, suggesting a cash runway of under a year given the $164M cash balance. The trajectory indicates that without sustained commercial revenue, the company will require additional financing.

The low capital intensity is typical for a clinical-stage biotech, where the primary investments are in R&D and clinical trials, not physical assets. The spike in CapEx/Revenue in 2025Q3 (61.1%) is an artifact of low revenue, not a change in investment strategy. This suggests that the company's cash burn is driven by operating expenses, not capital expenditures, and that future growth will not require significant fixed asset investment.

The positive working capital change in 2026Q2 contributed $11.5M to operating cash flow, offsetting some of the net loss. This is likely due to deferred revenue or accrued expenses related to the milestone. Investors should monitor whether these swings stabilize as the company transitions to commercial sales, as they currently mask the true cash burn rate.

The $17.1M buyback in 2026Q2 is notable given the company's cash constraints and negative cash flow. This could be an attempt to offset dilution from SBC, which totaled $9.0M in the same quarter. However, with a cash balance of $164M and a quarterly burn of ~$40M, the buyback consumes valuable runway. Investors should question whether this is the best use of capital versus funding clinical trials.

The large gap between net income and operating cash flow is primarily due to the $454.3M IPR&D charge in 2024Q2 and significant SBC expenses. This suggests that the company's economic losses are less severe than accounting losses, but the cash burn is still substantial. The cumulative cash burn of $300M over 2.5 years indicates a need for external financing, as the current cash balance covers less than a year of operations.